12/4
06:54 am
oric
Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs
Medium
Report
Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs
12/4
06:54 am
oric
Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs
Medium
Report
Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs
12/4
06:54 am
oric
Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs
Medium
Report
Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs
11/20
08:07 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $25.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $25.00 price target on the stock.
11/20
08:07 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $25.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $25.00 price target on the stock.
11/20
07:29 am
oric
Rating for ORIC
Medium
Report
Rating for ORIC
11/20
04:52 am
oric
Oric Pharmaceuticals initiated with an Outperform at Evercore ISI
Low
Report
Oric Pharmaceuticals initiated with an Outperform at Evercore ISI
11/20
04:52 am
oric
Oric Pharmaceuticals initiated with an Outperform at Evercore ISI
Low
Report
Oric Pharmaceuticals initiated with an Outperform at Evercore ISI
11/18
12:22 pm
oric
Rating for ORIC
Low
Report
Rating for ORIC
11/18
12:22 pm
oric
Rating for ORIC
Low
Report
Rating for ORIC
11/18
10:39 am
oric
Rating for ORIC
Low
Report
Rating for ORIC
11/18
09:00 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/18
09:00 am
oric
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/17
04:34 pm
oric
Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
Low
Report
Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
11/17
04:34 pm
oric
Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
Low
Report
Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
11/17
10:14 am
oric
Rating for ORIC
Low
Report
Rating for ORIC
11/17
10:14 am
oric
Rating for ORIC
Low
Report
Rating for ORIC
11/14
11:07 pm
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
11/14
11:07 pm
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
11/14
12:15 pm
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/14
10:08 am
oric
Rating for ORIC
Medium
Report
Rating for ORIC
11/14
10:08 am
oric
Rating for ORIC
Medium
Report
Rating for ORIC
11/14
08:12 am
oric
Rating for ORIC
Low
Report
Rating for ORIC
11/14
08:12 am
oric
Rating for ORIC
Low
Report
Rating for ORIC
10/27
11:08 pm
oric
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
Medium
Report
Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.